The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Leif Groop

Leif Groop

Principal investigator

Leif Groop

Fallbeskrivning. Rosiglitazonbehandling gav kraftfull effekt, men fick ändå avbrytas

A case report. Rosiglitazone treatment was highly effective yet had to be terminated

Author

  • Martin Ridderstråle
  • Leif Groop

Summary, in English

The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.

Department/s

  • Diabetes - Clinical Obesity
  • Genomics, Diabetes and Endocrinology

Publishing year

2002

Language

Swedish

Pages

407-410

Publication/Series

Läkartidningen

Volume

99

Issue

5

Document type

Journal article

Publisher

Swedish Medical Association

Topic

  • Endocrinology and Diabetes
  • Nutrition and Dietetics

Status

Published

Research group

  • Diabetes - Clinical Obesity
  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 0023-7205